PhilHealth signs up 20 hospitals to treat breast cancer-A A +A
Sunday, October 14, 2012
TWENTY hospitals nationwide have forged partnerships with the Philippine Health Insurance Corporation (PhilHealth) in a bid to address the country’s problem on breast cancer.
PhilHealth president and CEO Dr. Eduardo Banzon said they have enlisted the help of the 20 hospitals that have proven expertise in handling the disease.
These are the Jose R. Reyes Memorial Medical Center, East Avenue Medical Center, Philippine General Hospital, Rizal Medical Center, Quirino Memorial Medical Center, Baguio General Hospital, Ilocos Training and Regional Medical Center, Mariano Marcos Memorial Hospital and Medical Center, Cagayan Valley Medical Center, and Dr. Paulino J. Garcia Memorial Research and Medical Center.
Also in the list are the Jose B. Lingad Memorial General Hospital, Batangas Regional Hospital, Bicol Regional Teaching and Training Hospital, Bicol Medical Center; Western Visayas Medical Center, Corazon Locsin Montelibano Memorial Hospital, Vicente Sotto Memorial Medical Center, Northern Mindanao Medical Center, Southern Philippines Medical Center, and the Davao Regional Hospital.
“Negotiations are ongoing with additional public as well as private hospitals to serve as PhilHealth-contracted facilities,” Banzon said.
In the 20 PhilHealth-partner facilities, Banzon said their members in early stages of breast cancer can avail themselves of the breast cancer package amounting to P100,000.
The package, Banzon said, will fully cover the cost of treatment, hospitalization and professional fees.
“Breast cancer is an awfully nasty disease that destroys women at the prime of their lives. We are absolutely determined to help our women fight off the ailment,” said the health official.
Banzon said covering the early stage cancer is also the agency’s way to encourage early and timely detection of the disease since it is the “key to improved survival.”
Department of Health data show that one out of four Filipino women diagnosed with breast cancer die inside five years, and four out of 10 expire within a decade. (HDT/Sunnex)